Interactive Brokers Launches Ethereum Staking With Zerohash 
Samsung, SK Hynix Shares Plunge as China Chip Competition Grows 
South Korea Blocks 27 Crypto Exchange Websites in Regulatory Crackdown 
Bumble Shares Surge 50% on $1 Billion Buyout Talks 
CVS Pharmacy Agrees to $315 Million Opioid Settlement 
Arm Breaches Qualcomm License Deal, Jury Awards $2 
Visa Wins China Approval to Prepare Domestic Payments Expansion 
Most Americans Oppose Election Betting on Prediction Markets, Poll Finds 
Wells Fargo Expands Stablecoin Plans With 20 Major Banks 
Asian Stocks Plunge as AI Chip Selloff Hits South Korea and Japan 
MNX Crypto Exchange Launches Futures for OpenAI, Anthropic Valuations 
Fed’s Williams Sees One More Rate Hike in 2026, None in 2027 
US Dollar Slips From 18-Month High Ahead of Key Inflation Data 
S&P 500 Futures Rise Ahead of US Inflation Data and Bank Earnings 
Trezor Cuts Reseller Network After Ledger Security Breach 
SpaceX Starlink Restrictions Disrupt Ukraine Military Operations 
China Resumes US Soybean Purchases After Trump-Xi Summit 
Add as a preferred source on Google
Celltrion, a South Korean pharmaceutical company, formulated a COVID-19 antibody treatment, and it is reportedly ready to deliver the drug to the United States and Europe. With its new treatment, the company has now made the world’s third drug for coronavirus.
Now it is likely to enter the European and U.S. markets before this year ends, as per The Korea Herald. This information was revealed in a report that was released on Monday, Aug. 23.
Lee Dong Geon, an analyst at Shinhan Investment, said that Celltrion will be applying for the issuance of emergency use authorization for its Regkirona COVID-19 antibody treatment. It is hoped that the US Food and Drug Administration will approve this drug that is also called the CT-P59 for EUA.
Moreover, it was predicted that it would not be long until Celltrion’s Regkirona is approved. In fact, it may be out in the U.S. market as early as the fourth quarter of this year. As for the EU market, it was estimated that it could obtain regulatory approval from the Europen Medicine Agency before October since it is already under review.
Apparently, once Celltrion succeeded in rolling out Regkirona in the U.S. and Europe, the company’s position in the pharmaceutical business will surely improve, and this will be felt and observed in the coming months.
In any case, Rekirona is an antibody treatment for coronavirus, and it is the first drug to be developed by Celltrion. It already received a green light from South Korea, Indonesia, and recently, in Brazil. The pharma firm said that as soon as the EMA gives its approval, it will immediately ship the drug to the EU.
Celltrion said that this treatment could shorten the number of treatment days for patients with COVID-19. What’s more, it could also prevent the condition of patients from getting severe.
Meanwhile, as soon as the news of Celltrion’s possible shipment of Regkirona to major markets in the world, Pulse News reported that the company’s shares soared, gaining 6.77 percent to close at ₩284,000 or around $241.97 on Kospi. It was added that it finished 8.21 percent higher and Celltrion Healthcare also went up by 7.94 percent.
